Dr. Kevin J. Scanlon has the experience and expertise to enhance these relationships among the Biotechnology Community. His background includes: academic medicine, management in the pharmaceutical industry and an educator for graduate students interested in combining science and business. His unique career can facilitate concepts through the pharmaceutical pipeline. His career experience includes the following:

• Currently, he is working with entrepreneurs, the investment community and international governments in Europe, Asia and New Zealand to create an innovative culture around the intellectual property from their academic institutions.
• He is mentoring and supporting entrepreneurs through the venture capital community as a member of the Pasadena Angels and the Tech Coast Angels of Los Angeles. These organizations support entrepreneurs with seed round investments for their novel technology. (Investment Community)
• Dr. Scanlon has been a CEO in three start-up biotechnology companies: Xenex, Replivir and currently with Melanoma Diagnostics. These three early stage companies were created from academic research. Their early concepts were developed into validated clinical products for testing with patients. (Entrepreneur)
• Faculty educator for graduate business students involved in combining a business and science program to understand the Biotechnology industry. Faculty advisor for the FEMBA Global Access Program (www.gap.ucla.edu) and the EMBA Strategic Management Research Program (anderson.ucla.edu/x7886.xml) at UCLA School of Business. EMBA Flyer in Adobe PDF Format. (Teaching)
• As a Pharmaceutical Industry-Vice President, he was responsible for an international cancer (genomic) research program in the US, Europe and Asia. (Industry)
• Lead investigator on government and foundation grants, co-editor and co-founder of the Nature journal "Cancer Gene Therapy", authored over 130 original scientific articles and a member on federal grant review committees. (Science)